Cambridge, MA, United States

Constellation Pharmaceuticals

www.constellationpharma.com
Cambridge, MA, United States
SEARCH FILTERS
Time filter
Source Type

The present disclosure relates to a crystalline form of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, which is useful as an inhibitor of bromodomain-containing proteins. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders.


Patent
Genentech and Constellation Pharmaceuticals | Date: 2017-07-12

The present invention relates to compounds of formula (1): The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: Formula (1) wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.


Patent
Genentech and Constellation Pharmaceuticals | Date: 2017-07-26

The present invention relates to the use of CBP/EP300 inhibitors and BET inhibitors for the treatment of cancer. In some embodiments, the use is to treat cancer that is resistant to BET inhibitors.


Patent
Genentech and Constellation Pharmaceuticals | Date: 2017-03-20

The present invention relates to the use of CBP/EP300 inhibitors and BET inhibitors for the treatment of cancer. In some embodiments, the use is to treat cancer that is resistant to BET inhibitors.


Patent
Genentech and Constellation Pharmaceuticals | Date: 2017-07-12

The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.


Patent
Constellation Pharmaceuticals | Date: 2016-09-06

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.


Patent
Constellation Pharmaceuticals | Date: 2016-09-27

The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.


The present disclosure relates to a crystalline form of 2-((4S)-6-(4-chlorophenyl)-1- methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, which is useful as an inhibitor of bromodomain-containing proteins. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders.


Patent
Constellation Pharmaceuticals | Date: 2017-02-08

Described herein are novel methods for treating subjects with a cancer which is not overexpressing at least one of BCL-xL, BCL-w, and BAD, and optionally further overexpressing BCL-2. Also provided herein are tools for determining and/or assessing, and for the administration of, cancer treatments involving BET bromodomain inhibitors, BCL-xL inhibitors, or combinations thereof.


Patent
Genentech and Constellation Pharmaceuticals | Date: 2017-09-20

The present invention relates to compounds of formula (I): [INSERT FORMULA (1)] and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

Loading Constellation Pharmaceuticals collaborators
Loading Constellation Pharmaceuticals collaborators